u.s. leadership on covid, climate change and human rights, after a month of foreign policy crises. johnson & johnson booster shot, what the company is saying about the efficacy of a second dose of its covid vaccine. short supply, a crucial covid treatment is running low. how the government is deciding which states get the life-saving drug. terror plots thwarted, the new details from the f.b.i. as domestic terror investigations nearly triple. volcano emergency: more evacuations in spain, homes destroyed, swimming pools filling up with lava. and baby boom: the unexpected result when a c.e.o. boosted pay at the company. this is the cbs evening news with norah o donnell, reporting from the nation s capital. o donnell: good evening, to our viewers in the west and thank you for joining us. we are going to begin with breaking news. tonight, the f.b.i. announcing a medical examiner says the body found in wyoming on sunday was indeed that of gabby petito, the 22-year-old who
releases twoica nappeds seized after her arrest. later, the right moves: teaching kids life lessons using a chessboard. kids are just having fun. they don t realize that they re solving problems. this is the cbs weekend news. yuccas: good evening. i m jamie yuccas in los angeles. adriana diaz is off. this weekend, state health officials are rushing to help americans understand who qualifies for booster shots. there s urgency with the contagious delta variant still taking its toll. new infections over the past two weeks are down 16%, but covid deaths are up 26%. today in los angeles, one of the first cruise ships with covid outbreaks is returning to sea for the first time in 18 months. vaccinations required for all of those on board. cbs michael george leads us off with the latest. michael, good evening. reporter: jamie, good evening. people are already getting their booster shots at clinics like these, but in several states, many are refusing to still get even thei
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;.
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;.